Tags

Type your tag names separated by a space and hit enter

Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System.
Int J Mol Sci. 2020 Jun 13; 21(12)IJ

Abstract

Multiple sclerosis (MS) is characterized by peripheral and central inflammatory features, as well as demyelination and neurodegeneration. The available Food and Drug Administration (FDA)-approved drugs for MS have been designed to suppress the peripheral immune system. In addition, however, the effects of these drugs may be partially attributed to their influence on glial cells and neurons of the central nervous system (CNS). We here describe the molecular effects of the traditional and more recent FDA-approved MS drugs Fingolimod, Dimethyl Fumarate, Glatiramer Acetate, Interferon-β, Teriflunomide, Laquinimod, Natalizumab, Alemtuzumab and Ocrelizumab on microglia, astrocytes, neurons and oligodendrocytes. Furthermore, we point to a possible common molecular effect of these drugs, namely a key role for NFκB signaling, causing a switch from pro-inflammatory microglia and astrocytes to anti-inflammatory phenotypes of these CNS cell types that recently emerged as central players in MS pathogenesis. This notion argues for the need to further explore the molecular mechanisms underlying MS drug action.

Authors+Show Affiliations

Department of Molecular Animal Physiology, Donders Institute for Brain, Cognition and Behaviour, Centre for Neuroscience, Faculty of Science, Radboud University, 6525 AJ Nijmegen, The Netherlands. NeuroDrug Research Ltd., 6525 HP Nijmegen, The Netherlands.Department of Molecular Animal Physiology, Donders Institute for Brain, Cognition and Behaviour, Centre for Neuroscience, Faculty of Science, Radboud University, 6525 AJ Nijmegen, The Netherlands. NeuroDrug Research Ltd., 6525 HP Nijmegen, The Netherlands.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32545828

Citation

De Kleijn, Kim M A., and Gerard J M. Martens. "Molecular Effects of FDA-Approved Multiple Sclerosis Drugs On Glial Cells and Neurons of the Central Nervous System." International Journal of Molecular Sciences, vol. 21, no. 12, 2020.
De Kleijn KMA, Martens GJM. Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System. Int J Mol Sci. 2020;21(12).
De Kleijn, K. M. A., & Martens, G. J. M. (2020). Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System. International Journal of Molecular Sciences, 21(12). https://doi.org/10.3390/ijms21124229
De Kleijn KMA, Martens GJM. Molecular Effects of FDA-Approved Multiple Sclerosis Drugs On Glial Cells and Neurons of the Central Nervous System. Int J Mol Sci. 2020 Jun 13;21(12) PubMed PMID: 32545828.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System. AU - De Kleijn,Kim M A, AU - Martens,Gerard J M, Y1 - 2020/06/13/ PY - 2020/05/14/received PY - 2020/06/08/revised PY - 2020/06/10/accepted PY - 2020/6/18/entrez PY - 2020/6/18/pubmed PY - 2020/6/18/medline KW - astrocyte KW - dimethyl fumarate KW - fingolimod KW - glatiramer acetate KW - interferon-β KW - microglia KW - multiple sclerosis drug action KW - neuron KW - oligodendrocyte KW - teriflunomide JF - International journal of molecular sciences JO - Int J Mol Sci VL - 21 IS - 12 N2 - Multiple sclerosis (MS) is characterized by peripheral and central inflammatory features, as well as demyelination and neurodegeneration. The available Food and Drug Administration (FDA)-approved drugs for MS have been designed to suppress the peripheral immune system. In addition, however, the effects of these drugs may be partially attributed to their influence on glial cells and neurons of the central nervous system (CNS). We here describe the molecular effects of the traditional and more recent FDA-approved MS drugs Fingolimod, Dimethyl Fumarate, Glatiramer Acetate, Interferon-β, Teriflunomide, Laquinimod, Natalizumab, Alemtuzumab and Ocrelizumab on microglia, astrocytes, neurons and oligodendrocytes. Furthermore, we point to a possible common molecular effect of these drugs, namely a key role for NFκB signaling, causing a switch from pro-inflammatory microglia and astrocytes to anti-inflammatory phenotypes of these CNS cell types that recently emerged as central players in MS pathogenesis. This notion argues for the need to further explore the molecular mechanisms underlying MS drug action. SN - 1422-0067 UR - https://www.unboundmedicine.com/medline/citation/32545828/Molecular_Effects_of_FDA-Approved_Multiple_Sclerosis_Drugs_on_Glial_Cells_and_Neurons_of_the_Central_Nervous_System L2 - https://www.mdpi.com/resolver?pii=ijms21124229 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.